The U.S. presidential election is top of mind for many people, but medtech news continued to roll out on MassDevice this past week.
Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss the week’s “Newmarker’s Newsmakers” — as try out new, “exciting” sound effects — during our DeviceTalks Weekly podcast.
Without further ado, here’s this week’s MassDevice Top Five:
5. GE Healthcare debuts breast cancer tech
GE Healthcare (NYSE:GE) has made its Serena Bright biopsy technology available in the U.S. The company touts Serena Bright as the industry’s first contrast-enhanced guided biopsy solution. Read the full story here.
4. Merit Medical settles physician kickback suit for $18M
Merit Medical (NSDQ:MMSI) recently agreed to pay $18 million to resolve allegations that the company paid kickbacks to physicians to use its embolization and occlusion products. Read the full story here.
3. Guess who the pharma industry is supporting for president
The pharma industry has put its weight behind Democratic presidential candidate Joe Biden, reversing a longstanding fundraising trend that has favored the GOP. Read the full story here.
2. FDA issues EUAs for two at-home COVID-19 tests
Two companies announced that they received FDA emergency use authorizations (EUAs) for at-home COVID-19 diagnostic tests. Eurofins (Paris:ERF.PA) and DxTerity Diagnostics each received the authorization for separate COVID-19 tests, one of which is nasal-based and the other saliva-based. Read the full story here.
1. Are Stephen Hahn’s days numbered at FDA?
HHS Secretary Alex Azar has been reportedly discussing the removal of Dr. Stephen Hahn as FDA commissioner, according to Politico. The Politico report cited a half dozen current and former administration officials. Read the full story here.